News

Recent share performance and business profile Tempus AI (TEM) has drawn investor attention after a period in which the stock fell 22% over the past month and 17% over the past 3 months, while its core healthcare technology operations remain focused on clinical and research applications. See our latest analysis for Tempus AI. At a share price of $43.62, Tempus AI has seen its recent momentum fade, with the share price return down 10% over the past week, 22% over the past month and 30% year to...

Tempus AI and Bristol Myers Squibb are expanding their collaboration to apply AI analytics and real world data to oncology and neuroscience drug development. The partnership focuses on using Tempus AI's multimodal patient data to inform clinical trial design, including programs in oncology and Alzheimer's disease. The agreement highlights growing pharmaceutical interest in AI driven tools that can address complex challenges in precision medicine research. Tempus AI, listed as NasdaqGS:TEM,...

Healthcare AI stocks have been hammered in 2026, with several names down 30% to 65% year to date even as their underlying platforms keep maturing. That dislocation between share price and product progress is exactly the kind of setup retail investors should scan for: real revenue, real partnerships, and prices low enough that a successful ... 7 Healthcare AI Stocks Under $50 With Huge Upside Potential

By Daniella Parra Imviva Biotech said data showed its CTA313 drug resulted in 50% of patients going into remission for systemic lupus. Many patients experience incomplete responses, recurrent flares and long-term treatment-related toxicity, it said. “The clinical activity observed with CTA313 in systemic lupus erythematosus is highly encouraging, with 100% of patients achieving an SRI-4 […]

We just covered Cathie Wood’s 11 Biggest AI and Data Center Stock Picks. Tempus AI Inc. (NASDAQ:TEM) ranks #5 (see Cathie Wood’s 5 Biggest AI and Data Center Stock Picks). Cathie Wood’s Stake: $446,275,249 Tempus AI Inc. (NASDAQ:TEM) is an AI healthcare play in Cathie Wood’s portfolio. It’s a healthcare diagnostics and data platform that builds large-scale […]

Tempus AI (NasdaqGS:TEM) and Lucent Diagnostics, a Quanterix company, are teaming up to bring an AI-enabled care pathway and blood test for Alzheimer's detection into clinical workflows. The collaboration centers on integrating the LucentAD Complete blood-based biomarker panel into Tempus's Next platform for use by neurologists. The partnership extends Tempus AI's reach beyond oncology into neurology and broader precision medicine applications. Tempus AI, trading at around $49.43 per share,...

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.6% and the actively trad

Beneath the headline noise of a Q1 2026 beat and raised guidance, the critical insight for Tempus AI lies in a structural tug of war between an accelerating data moat and a currently elevated cost structure. The market is focusing on the 36% year over year top line growth to $348.1 million. The true alpha driver is hidden within the unit economics of the Data and Applications segment. This division is actively shifting the company from a traditional diagnostics provider to a recurring revenue he

Tempus AI (NASDAQ:TEM) reported first-quarter 2026 revenue of $348.1 million, up a little over 36% year over year, as the company posted growth across both its diagnostics and data and applications segments and raised its full-year outlook. Founder and CEO Eric Lefkofsky said diagnostics revenue ca

Moby summary of Tempus AI, Inc.'s Q1 2026 earnings call

Tempus (TEM) delivered earnings and revenue surprises of +38.10% and +0.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Investors are watching Tempus AI (NASDAQ:TEM) ahead of first-quarter results due after the close tomorrow. The stock burst into investor consciousness in January 2025 after Nancy Pelosi disclosed a position, ran past $100, and has since shed nearly half its value. From Pelosi Halo to Show-Me Story Pelosi’s market-beating track record has turned her trades ... Can Nancy Pelosi’s Favorite AI Stock Hope to Regain Its Momentum?

In April 2026, the Keck School of Medicine of USC and Keck Medicine of USC announced a broad collaboration with Tempus AI to embed its genomic testing, AI tools, and data platform across more than 1.5 million annual patient visits in their Southern California network. This partnership not only expands Tempus AI’s clinical footprint but also deepens its access to real-world oncology data, reinforcing the company’s core data-network advantage in precision medicine. With this USC collaboration...

Fulgent Genetics (FLGT) delivered earnings and revenue surprises of -89.47% and +4.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Tempus AI Inc. (NASDAQ:TEM) is one of the best up and coming stocks with highest upside potential. On April 23, Tempus AI and the Keck School of Medicine of USC launched a multi-faceted collaboration aimed at integrating artificial intelligence and data-driven insights into Southern California’s healthcare landscape. This partnership will impact over 1.5 million annual […]

Is TEM a good stock to buy? We came across a bullish thesis on Tempus AI, Inc. on Joe Gannon’s Substack by Gannon Capital. In this article, we will summarize the bulls’ thesis on TEM. Tempus AI, Inc.’s share was trading at $56.78 as of April 20th. TEM’s trailing P/E was 39.30 according to Yahoo Finance. Tempus AI, Inc. operates as […]

TEM and ILMN battle in precision oncology, but stronger stock gains, valuation and earnings outlook position ILMN as the more compelling pick now.

Tempus AI (TEM) has been drawing attention after recent share price moves, with the stock showing a gain over the past month but a decline across the past 3 months and year to date. See our latest analysis for Tempus AI. The recent 10.61% 1 month share price return contrasts with a 16.38% 3 month share price decline and a 19.79% year to date share price loss. Recent momentum therefore appears more like a short term bounce than a sustained trend, even though the 1 year total shareholder return...

The blended fair value estimate for Tempus AI has been adjusted slightly, moving from US$72.73 to US$72.40 as part of the latest round of analyst model updates. This small shift sits against a mixed research backdrop, where some firms are lifting targets after Q4 while others are trimming estimates and highlighting questions around data monetization, partnerships and the balance between growth and visibility. As you read on, you will see how to track these moving pieces and what to watch as...

Tempus AI (NasdaqGS:TEM) was named to TIME’s 10 Most Influential Health and Life Science Companies of 2026. The company expanded its clinical and research reach through a multi year collaboration with the Keck School of Medicine of USC and Keck Medicine of USC. The partnership is aimed at advancing AI driven precision medicine and applying Tempus tools across patient care and research programs. Tempus AI focuses on applying artificial intelligence to precision medicine, with products that...

TruBridge (TBRG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TEM faces pressure ahead of Q1 earnings as macro headwinds, high valuation and estimate trends cloud its near-term investment appeal.